27/02/2015 20:58:09 Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
02/24/20154:05PMGLOBEMyriad Board Approves $200 Million Increase in Share Repurchase Program
SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of December 31, 2014, the Company has repurchased almost $1 billion of stock since the inception... More...>>
02/17/20159:10AMPRNUSGeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing Patent Dispute with Myriad Gen...
GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing Patent Dispute with Myriad Genetics PR Newswire WASHINGTON, Feb. 17, 2015 WASHINGTON, Feb. 17, 2015 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox P.L.L.C., an intellectual property law firm in Washington, DC, announced... More...>>
02/06/20151:00PMGLOBEMyriad Genetics to Present at the 2015 Leerink Global Healthcare Conference
SALT LAKE CITY, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the Leerink Global Healthcare Conference at 1:00 p.m. Eastern on February 12, 2015, at the Waldorf Astoria in New York, New York. The... More...>>
02/03/20154:10PMGLOBEMyriad Announces Retirement of Peter D. Meldrum, President and CEO
SALT LAKE CITY, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board... More...>>
02/03/20154:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
Revenues of $184.4 Million Adjusted Diluted EPS of $0.40, and Diluted EPS of $0.32 myRisk™ Hereditary Cancer Revenues of $85.1 Million BRACAnalysis CDx™ Approved by the FDA Tumor BRACAnalysis CDx™ Granted European CE Marking Approval Company Revises Fiscal Year 2015 Financial Guidance; Provides Fiscal... More...>>
01/22/20157:05AMGLOBEMyriad Genetics Names Johnathan M. Lancaster as Vice President of Medical Affairs
SALT LAKE CITY, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Johnathan M. Lancaster, M.D., Ph.D. has joined the Company as the vice president of Medical Affairs for Oncology, Myriad Genetic Laboratories, effective Feb. 9, 2015. In this new role, Dr. Lancaster will provide medical... More...>>
01/21/20154:05PMGLOBEMyriad Genetics to Announce 2Q15 Financial Results on February 3, 2015
SALT LAKE CITY, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal second quarter 2015 and provide a business update following the close of market on Tuesday, February 3, 2015. The Company also will host a conference call at 4:30 p.m... More...>>
01/20/20157:05AMGLOBEMyriad RBM Joins Institut Pasteur in the Global Fight Against Tuberculosis
SALT LAKE CITY, Jan. 20, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This research project is funded by the Bill... More...>>
01/08/201512:05AMONEMyriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
Identifies Up to 44 Percent More Eligible Patients Than Conventional BRCA Tests SALT LAKE CITY and ZURICH, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Company has obtained CE Marking in Europe for its Tumor BRACAnalysis CDx test, which identifies tumors that have mutations in... More...>>
01/08/201512:05AMGLOBEMyriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors...
SALT LAKE CITY and ZURICH, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Company has obtained CE Marking in Europe for its Tumor BRACAnalysis CDx test, which identifies tumors that have mutations in the BRCA1 or BRCA2 genes. Tumor BRACAnalysis CDx is the first and only tumor-based... More...>>
01/05/20154:05PMGLOBEMyriad Genetics to Present at the 2015 J.P. Morgan Annual Healthcare Conference
SALT LAKE CITY, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 9:30 a.m. Pacific on January 12, 2015, at the Westin St. Francis in San Francisco... More...>>
12/22/20147:00AMGLOBEMyriad Genetics Names Bernard Tobin as President of Crescendo Bioscience
SALT LAKE CITY, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of Bernard F. Tobin as president of Crescendo Bioscience, effective January 5, 2015. Mr. Tobin will report to Peter D. Meldrum, president and CEO, Myriad Genetics, Inc., and will succeed William Hagstrom... More...>>
12/19/201412:10PMGLOBEMyriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM) (olaparib) in Ovarian Cancer Pa...
SALT LAKE CITY, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's drug Lynparza™ (olaparib). Lynparza... More...>>
08/13/20149:47AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Macy's Inc. (M), Deere & Co. (DE) and Seaworld Entertainment Inc. (SEAS). Macy's reported disappointing second-quarter results and reduced its sales outlook for the year, adding more concern to an already struggling retail sector... More...>>
07/30/201412:00PMGLOBEMyriad Genetics to Announce Financial Results for the Fiscal Fourth Quarter and Full Year 2014 on August 12, 2014
SALT LAKE CITY, July 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014. The Company also... More...>>
06/10/20144:05PMGLOBECrescendo Bioscience to Present Multiple Studies at 2014 EULAR Meeting
Vectra® DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage SALT LAKE CITY, June 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that Vectra® DA data will be featured in eight posters at the 2014 European... More...>>
06/09/20144:05PMGLOBEMyriad Announces Retirement of James Evans, Chief Financial Officer
SALT LAKE CITY, June 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Company's CFO until... More...>>
06/03/20147:05AMGLOBEMyriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, June 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35th annual Goldman Sachs Global Healthcare Conference, at 10:40 a.m. Pacific on June 10, 2014, at the Terranea Resort in Rancho Palos Verdes... More...>>
06/02/201410:45AMGLOBEMyriad Genetics Announces Participation in Innovative Collaboration to Accelerate Hereditary Cancer Research
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically... More...>>
06/02/20147:05AMGLOBEMyriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented several clinical studies on the Myriad myRisk™ Hereditary Cancer test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. Among the important new findings is that the myRisk... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq mygn150227 20:58